Revenue Forecast For Investigational Therapeutic – Free Tool February 19, 2020
BioHeights has launched a new tool that allows to forecast revenue for an investigational therapeutic. In the main menu, go to Tools – Revenue Forecast Calculator. Why should you give it a try? Building your own drug revenue forecast model from scratch is time consuming. Instead, you can test your product and market assumptions using…
Learn More
The Man Who Speaks on Behalf of ALL Children October 17, 2019
The First CAR T Patient Story Revisited The only child’s cancer diagnosis, remission and then relapse, oncology ward, remission again, lost cure, relapse again, hospice recommendations, coma, long coma – these were 2 years in the life of Tom Whitehead seven years ago. Tom is the father of the first child who received CAR T…
Learn More
Anti-CD19 CAR T Kymriah and Yescarta Race to Market Infographic September 1, 2019
Two anti-CD19 CAR T cell therapies are currently approved by the FDA to treat hematologic malignancies: Kymriah and Yescarta. Both therapies have the same mechanism of action and treat relapsed/refractory B-cell malignancies such as acute lymphoblastic leukemia (ALL) and large B-cell lymphoma (LBCL). Click to zoom in. Anti-CD19 CAR T Race to Market The infographic…
Learn More
Jeff Marrazzo Tells His Spark Story July 1, 2019
On June 2, I attended the Entrepreneurial Bootcamp at the BIO Convention in Philadelphia. The Keynote speaker was Jeff Marrazzo, the CEO of Spark Therapeutics. The goal of his talk was to tell us about the early days of Spark, when it was the company of 1 (or of 1.5). Building a biopharma/biotech startup from…
Learn More
ASGCT 2019 Insights: Cell and Gene Therapies Tackle 160+ Disorders May 10, 2019
The American Society of Gene and Cell Therapy (ASGCT) annual meeting on Apr 28 – May 2 in Washington D.C. was superb. It brought together several thousands attendees. Prof. Steven Gray wittily noted that the number of attendees was similar to the number of orphan diseases. Hence, each of us should get to work. Arguably,…
Learn More
AAV Gene Therapy Clinical Trials Target Over 50 Diseases April 1, 2019
This article discusses diseases targeted in AAV gene therapy clinical trials initiated since 2003 through January 2019. It includes interventional, long-term follow up, and some observational studies. The review also covers industry sponsor involvement, volume of trials in each disease, and most advanced clinical development achieved in each indication to date. As of January 2019,…
Learn More
< 1 2 3 >

Sign Up to Receive the Latest Insights
Enter your email address to receive notifications about new articles, tools, and updates.
Sign Up Here